NASDAQ$AHCO
AdaptHealth Corp. · Q1 2022 earnings
Q1 2022 earnings · · Investor relations
Briefing
Announced first quarter 2022 results and updated 2022 guidance, along with a $200 million share repurchase program.
AdaptHealth reported strong first-quarter results, driven by continued strength in the diabetes product line and resilient HME product line. The company is updating its previously issued financial guidance for fiscal year 2022 and announced the authorization of a share repurchase program for up to $200 million.
- Saw continued strength in diabetes product line, consistent with expectations.
- HME product line continues to be resilient as CPAP patient set ups in March and April were at or near 2021 levels.
- Operating and financial results demonstrate the Company’s strong position as a leading national provider of medical equipment and supplies across the U.S.
- Announced a $200 million share repurchase program, reflecting confidence in AdaptHealth’s outlook.
Headline financials
Revenue & EPS history
AdaptHealth · Revenue · Quarterly
$706M
Forward guidance
AdaptHealth updated its previously issued financial guidance for fiscal year 2022, based on current business, market trends, governmental reimbursement updates, and acquisitions to date. Guidance for fiscal year 2022 does not include any contribution from acquisitions that have not yet closed, or continuing Public Health Emergency benefits beyond the currently scheduled expiration date.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q1 2022
+0.6%
Avg return
Earnings day
+1.4%
Avg return
5 days after
+1.6%
Avg return
30 days after
52%
16 / 31 earnings
Positive
+34.6%
Q4 2023
Best reaction
-27.9%
Q4 2022
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -10.0% | -13.4% | -25.6% | |
| Q4 2025 | -14.2% | -11.1% | +10.9% | |
| Q3 2025 | +17.2% | +4.5% | +3.2% | |
| Q1 2025 | +1.7% | -1.4% | +3.7% | |
| Q4 2024 | +24.4% | +33.1% | +24.4% | |
| Q3 2024 | +0.3% | -0.6% | -4.2% | |
| Q2 2024 | -17.2% | -14.1% | +4.6% | |
| Q1 2024 | -8.6% | -8.8% | +4.9% | |
| Q4 2023 | +34.6% | +37.9% | +50.9% | |
| Q3 2023 | -23.1% | -18.6% | -5.6% | |
| Q2 2023 | +11.1% | +4.4% | -19.8% | |
| Q1 2023 | -8.4% | -12.2% | -13.8% | |
| Q4 2022 | -27.9% | -27.9% | -40.6% | |
| Q3 2022 | -1.6% | +8.4% | +4.5% | |
| Q2 2022 | -8.9% | -8.2% | -25.7% | |
| Q1 2022 | +23.7% | +42.2% | +53.6% | |
| Q4 2021 | +4.1% | +2.3% | +2.8% | |
| Q3 2021 | -5.4% | -7.2% | -24.1% | |
| Q2 2021 | +16.4% | +13.4% | +12.3% | |
| Q1 2021 | -8.5% | -14.9% | -10.4% | |
| Q4 2020 | +2.1% | +12.4% | +21.7% | |
| Q3 2020 | +2.6% | +0.6% | +19.5% | |
| Q2 2020 | +13.9% | +18.0% | +7.0% | |
| Q1 2020 | +1.6% | +5.8% | +5.5% | |
| Q4 2019 | +1.8% | +1.4% | -7.7% | |
| Q3 2019 | -4.1% | -4.9% | -3.3% | |
| Q2 2019 | +0.0% | +0.0% | -0.6% | |
| Q1 2019 | +0.0% | +0.0% | +0.3% | |
| Q4 2018 | +0.6% | +0.7% | +1.3% | |
| Q3 2018 | +0.3% | +0.1% | +0.4% | |
| Q2 2018 | +0.0% | +0.3% | +0.1% | |
| Q1 2018 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro